3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
22
Lymphoma, Large B-Cell, Diffuse
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Lymphoma, Follicular
12
Lymphoma
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Rhabdomyosarcoma
8
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, B-Cell
6
Leukemia, Biphenotypic, Acute
6
Wilms Tumor
5
Sarcoma, Ewing
5
Recurrence
5
Neuroblastoma
5
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, T-Cell
4
Rhabdomyosarcoma, Embryonal
3
Medulloblastoma
3
Lymphoproliferative Disorders
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Down Syndrome
3
Sarcoma
2
Rhabdomyosarcoma, Alveolar
2
Rhabdoid Tumor
2
Plasmablastic Lymphoma
2
Osteosarcoma
2
Interventions
Cyclophosphamide
3
acalabrutinib
2
Rituximab
2
pembrolizumab
1
obinutuzumab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Doxorubicin
1
CA-4948
1
Busulfan
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
Vincristine
×
90 days
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled